Pulmonary infiltrates after cytokine therapy for stem cell transplantation: Massive deposition of eosinophil major basic protein detected by immunohistochemistry

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 4, 1999, Pages 1361-1365

  O'Hearn, Daniel J ^a,b   Leiferman, Kristin M ^a,b   Askin, Frederick ^a,b   Georas, Steve N ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DIURETIC AGENT; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; MAJOR BASIC PROTEIN; METHOTREXATE; THIOTEPA;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CARCINOMA; BRONCHUS BIOPSY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; EOSINOPHILIA; FEMALE; HUMAN; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFILTRATE; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032848407     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.4.9902048     Document Type: Article

References (38)

1. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240:1109-1176.
2. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J.A.M.A. 271:907-913.
3. Rosenbcrg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492.
4. Noga, S. J., L. Hornwitz, H. Kim, M. K. Laulis, and A. D. Hess. 1992. Interferon-gamma potentiates the anti-tumor effect of cyclosporine-induced autoimmunity. J. Hematother. 1:75-84.
5. Kennedy, M. J., G. B. Vogelsang, R. J. Jones, F. R. Farmer, A. D., Hess, V. Altomonte, A. M. Huelskamp, and N. E. Davidson. 1994. Phase 1 trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 12:249-257.
6. Kennedy, M. J. 1994. Induced autologous graft-versus-host disease for the treatment of cancer. Cancer Treat. Rev. 20:97-103.
7. Lotze, M. T., Y. L. Matory, A. A. Raynor, S. E. Ettinghausen, J. T. Vetto, C. A. Seipp, and S. A. Rosenbcrg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764-2772.
8. Morassut, S., L. Balestreri, E. Galligioni, F. Coran, and C. Sacco 1992. Radiologie characteristics of the thorax during therapy with interleukin-2. Radiol. Med. (Torino) 84:368-371.
9. Rosenstein, M., S. E. Ettinghausen, and S. A. Rosenberg. 1986. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. 137:1735-1742.
10. Filley, W. V., K. F., Holley, G. M. Kephart, and G. J. Gleich. 1982. Identification by immunofluorescence of eosinophil granule major basic protein In lung tissues of patients with bronchial asthma. Lancet 2:11-15.
11. Breast Cancer Working Committee of the Autologous Blood and Marrow Transplant Registry of North America. 1997. High dose chemotherapy with autologous hemalopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol. 15:1870-1879.
12. Hess, A. D., and A. C. Fischer. 1989. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantaion 48:895-900.
13. Yron, I., T. A. Wood, P. J. Spiess, and S. A. Rosenherg. 1980 In vitro growth of murine T Cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 125:238-245.
14. Lotze, M. T., F. A. Grimm, A. Mazumder, J. L. Strausser, and S. A. Rosenberg, 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 41:4420-4425.
15. Grimm, E. A., A. Mazumder, H. Z. Zhang, and S. A. Rosenbcrg. 1982. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp. Med. 155:1823-1841.
16. Mesler Muul, L., P. J. Spiess, E. P. Director, and S. A. Rosenberg, 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989-995.
17. Itoh, K., C. D. Platsoucas, and C. M. Balch. 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J. Exp. Med. 168:1419-1441.
18. Rivoltini, L., V. Viggiano, S. Spinazze, A. Santoro, M. P. Colombo, K. Takatsu, and G. Parmiani. 1993. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2: role of interleukin 5, Int. J. Cancer 54:8-15.
19. Schwartz, R., F. Momburg, G. Moldenhauer, B. Dorken, and V. Schirrmacher. 1985. Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma. Int. J. Cancer 35:245-250.
20. Klempner, M. S., R. Noring, J. W. Mier, and M. B. Alkins. 1990. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med. 322:959-965.
21. Lotze, M. T., Y. L. Matory, S. E. Ettinghausen, A. A. Rayner, S. O. Sharrow, C. A. Seipp, M. C. Custer, and S. A. Kosenberg. 1985. In vivo administration of purified human interleukin 2. J. Immunol. 135;2865-2875.
22. Lee, R. E., M. T. Lotze, J. M. Skibber, H. Tucker R. O, Bonow, F. P. Ognibene, J. A. Carrasquillo, J. H. Shelhammer, J. E. Parrillo, and S. A. Rosenberg. 1989. Cardiorespiratory effects of immunotherapy with interleukin-2, J. Clin, Oncol. 7:7-20.
23. Ognibene, F. P., S. A. Rosenberg, M. T. Lotze, J. M. Skibber, M. M. Parker, J. H. Shelhammer, and J. E. Parrillo. 1988. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750-754.
24. Downie, G. H., U. S. Ryan, B. A. Hayes, and M. Friedman, 1992. Interleukin-2 directly increases atbumin permeability of bovine and human vascular endothelium in vitro. Am. J. Respir. Cell Mol. Biol. 7:58-65.
25. Yamaguchi, Y., T. Suda, H. Shiozaki, Y. Miura, Y, Hitoshi, A. Tominaga, K. Tukutsu and T. Kasahara. 1990, Role of IL-5 in IL-2-induced eosinophilia. J. Immunol. 145:873-877.
26. Macdonald, D., A. A. Gordon, H. Kajitani, H. Enokihara, and A. J. Barrett. 1990. Interleukin-2 treatment-associated cosinophilia is mediated by interteukin-5 production. Br. J. Haematol. 76:168-173.
27. Lopez, A. E., C. G. Begley, D. J. Williamson, D. J. Warren, M. A. Vadas, and C. J. Sanderson. 1986. Murine eosinophil differentiation factor: an eosinophil-specific colony-stimulating factor with activity for human cells. J. Exp. Med. 163:1085-1099.
28. Lopez, A. E., C. J., Sanderson, J. R. Gamble, H. D. Campbell, I. G. Young, and M. A. Vadas, 1988. Recombinant human interleukin 5 is a selective activator of human ensinophil function. J. Exp. Med. 167:219-224.
29. van Haelst Pisani, C., J. S. Kovach, H. Kata, K. M. Leiferman, G. J. Gleich, J. F. Silver, R. Dennin, and J. S. Abrams. 1991, Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patient with cancer. Blood 78:1538-1544.
30. Gleich, G. J., E. Frigas, D. A. Loegering, D. L. Wassom, and D. Steinmuller, 1979. Cytotoxic properties of the eosinophil major basic protein. J. Immunol. 123:2925-2927.
31. Ayars, G. H., I., C. Altman, G. J. Gleich, D. A. Loegering, and C. B. Baker. 1985. Eosinophil and eosinophil granule-mediated pneumocyte injury. J. Allergy Clin, Immunol. 76:595-604.
32. Leiferman, K. M., H. A. Sampson, H. S. Haugen, P. Y. Venencic, and G. J. Gleich. 1985. Dermal deposition of eosinophil granule major basic protein in atopic dermatitis. N. Engl. J. Med. 313:282-285.
33. Mani, S., and W.-J. Poo. 1996. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am. J. Clin. Oncol, 19:149-153.
34. Hartnell, A., A. B. Kay, and A. J. Wardlaw. 1992. IFN-gamma induces expression of Fc Gamma RIII (CD16) on human eosinophils. J. Immunol. 148:1471-1478.
35. Meagher, L. C., J. M. Cousin, J. R. Seekl, and C. Haslett. 1996. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156:4422-4428.
36. Grantham, J. G., J. A. Meadows III, and G. J. Gleich. 1986. Chronic eosinophilic pneumonia. Am. J. Med. 80:89-94.
37. Fox, B., and W. A. Seed. 1980. Chronic eosinophilic pneumonia. Thorax 35:570-580.
38. Gaensler, E. A., and C. A. Carrington. 1977. Peripheral opacities in chronic cosinophilic pneumonia: the photographic negative of pulmonary oedema. A.J.R. 128:1-13.